Abstract
Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Keywords: Blood pressure, diabetes mellitus, renin-angiotensin-system, diabetic retinopathy, DIRECT, NAVIGATOR, DREAM, EUCLID
Current Pharmaceutical Biotechnology
Title: The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy
Volume: 12 Issue: 3
Author(s): V. Swetha E. Jeganathan
Affiliation:
Keywords: Blood pressure, diabetes mellitus, renin-angiotensin-system, diabetic retinopathy, DIRECT, NAVIGATOR, DREAM, EUCLID
Abstract: Research has proven that blood pressure is an important modifiable risk factor for diabetic retinopathy and that lowering high blood pressure significantly reduces the development and progression of retinopathy in both type 1 and type 2 diabetic patients. The renin-angiotensin-system (RAS) has been shown to become activated in diabetes. Hyperglycemia stimulates the angiotensin AT1-receptor and downstream chains of events resulting in diabetic end organ damage. Pharmacological RAS inhibition may thus be a beneficial therapeutic strategy in the management of diabetic retinopathy. The present review article details therapeutic RAS inhibition in diabetic retinopathy with an emphasis on recently published evidence. Future research on the potential effects of RAS blockade will be important while using these drugs as adjuncts in the treatment of diabetic retinopathy.
Export Options
About this article
Cite this article as:
Swetha E. Jeganathan V., The Therapeutic Implications of Renin-Angiotensin System Blockade in Diabetic Retinopathy, Current Pharmaceutical Biotechnology 2011; 12 (3) . https://dx.doi.org/10.2174/138920111794480615
DOI https://dx.doi.org/10.2174/138920111794480615 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Micro RNA: An Epigenetic Regulator of Type 2 Diabetes
MicroRNA Anti-Inflammatory Actions of the Heme Oxygenase-1 Pathway
Current Pharmaceutical Design Effect of Antioxidant Extract from Cherries on Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Adult Stem Cells and Extracellular Vesicles in Acute and Chronic Kidney Injury
Current Regenerative Medicine (Discontinued) A Systematic Review of a Naturally Occurring Iridoid: Catalpol
Current Bioactive Compounds Leptin and the Cardiovascular System: A Review
Recent Patents on Cardiovascular Drug Discovery Genomics, Proteomics and Metabolomics Approaches for Predicting Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Editorial [Hot topic: Proteinuria in Diabetes: an Endocrine Disease? (Guest Editor: Alessia Fornoni and Oliver Lenz)]
Current Diabetes Reviews Benefits of SGLT2 Inhibitors Beyond Glycemic Control – A Focus on Metabolic, Cardiovascular and Renal Outcomes
Current Diabetes Reviews Subject Index to Volume 10
Current Pharmaceutical Design Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets Gene Regulation of Aldose-, Aldehyde- and a Renal Specific Oxido Reductase (RSOR) in the Pathobiology of Diabetes Mellitus
Current Medicinal Chemistry Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases
Current Topics in Medicinal Chemistry Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Painful Peripheral Neuropathies
Current Neuropharmacology